Not currently recruiting at UCSD
The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Ocugen
- Links
- Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa
- ID
- NCT05203939
- Phase
- Phase 1/2 Retinitis Pigmentosa Research Study
- Study Type
- Interventional
- Participants
- Expecting 18 study participants
- Last Updated